Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated, autoimmune disease of the central nervous system (CNS) that serves as a model for various cellular and molecular aspects of the human disease, multiple sclerosis (MS). Although EAE has long been considered a T cell-mediated disease, macrophages play a role in disease pathogenesis and are known to accumulate in the CNS under the control of chemokines. In the present report we demonstrate that mice induced to develop EAE were treated with a small molecular weight molecule that suppresses proinflammatory cytokine production which resulted in significantly decreased clinical EAE, CNS CCL2 expression and CNS macrophage accumulation. These results demonstrate the efficacy of a novel class of therapeutic molecules for CNS demyelinating disease.
Introduction
Experimental autoimmune encephalomyelitis (EAE) is a T cell-mediated demyelinating disease of the central nervous system (CNS) that serves as a model for multiple sclerosis (MS) (Steinman and Zamvil, 2006) . In addition to the requirement for autoreactive T cells, macrophages have been shown to be necessary for EAE development (Brosnan et al., 1981; Cua et al., 1995) .
Many chemokines are expressed in the CNS of mice that develop EAE (Godiska et al., 1995) . Deletion or neutralization of CCL2 (Huang et al., 2001; Kennedy et al., 1998) as well as deletion of its receptor, CCR2 (Fife et al., 2000) decreased EAE severity. CCL2 (McManus et al., 1998) has been suggested to be involved in MS. Chemokines have been postulated to regulate accumulation of inflammatory cells in the CNS during EAE/MS pathogenesis (Karpus and Ransohoff, 1998) .
The development of therapeutics for MS has recently focused on preventing or reducing CNS accumulation of inflammatory cells. Anti-CD49d antibody treatment of mice had a dramatic effect of preventing accumulation of inflammatory cells in the CNS (Yednock et al., 1992) . In fact, the ability of Tysabri® to dramatically improve disability in MS patients (Rice et al., 2005) underscores the desirability of this approach. To that end we investigated a novel compound, Minozac (Mzc) (Hu et al., 2007) , for its ability to prevent accumulation of inflammatory cells in the CNS and inhibit EAE.
Materials and methods

Mice
Female SJL (H2s) mice were purchased from Harlan Sprague Dawley (Indianapolis, IN) and used as previously described (Karpus et al., 1995) . Animal care and use was in accordance 
